<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529191</url>
  </required_header>
  <id_info>
    <org_study_id>2006-5-4824</org_study_id>
    <secondary_id>R01FD003340</secondary_id>
    <nct_id>NCT00529191</nct_id>
  </id_info>
  <brief_title>Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)</brief_title>
  <acronym>TIDM</acronym>
  <official_title>Phase II, Double Blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin in Subjects With Newly Diagnosed Type 1 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this application is to evaluate the safety and efficacy of atorvastatin as a
      potential treatment to preserve beta cell function in children and young adults with newly
      diagnosed type 1 diabetes (T1DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes is an autoimmune disease that is characterized by destruction of the
      insulin-producing beta cells of the pancreas. T1DM therapy requires insulin administration,
      either by multiple daily injections or by insulin pump. However, in many patients, blood
      sugar control remains suboptimal and complications develop that shorten life expectancy and
      severely impact quality of life. At the time of diagnosis, most patients still have
      significant residual beta cell function. Previous research has shown that weakening the
      immune system's attack on the pancreatic beta cells may help to preserve or potentially
      increase insulin production.

      Preliminary studies have shown that members of the statin family of medications, including
      atorvastatin (Lipitor®), preserve beta cell function in a mouse model of type 1 diabetes.
      These finding suggest that use of atorvastatin in combination with insulin therapy may delay
      and potentially reverse the destruction of beta cells in patients who have recently developed
      type 1 diabetes. Atorvastatin (Lipitor®) is approved for use in adults and children (&gt;10
      years of age) who have elevated blood cholesterol levels. This study will examine whether
      atorvastatin (Lipitor®) may also help the body preserve insulin production in patients with
      newly diagnosed (within 8 weeks) type 1 diabetes.

      Patients will be randomly assigned to take either atorvastatin (Lipitor®) or placebo. Two out
      of every 3 patients will receive atorvastatin and 1 out of 3 will get placebo. As this is a
      double-blinded study, neither the care team nor the patient will know if they are actually
      taking atorvastatin (Lipitor®). Patients who have given consent to participate in the study
      and pass the required screening tests will take the assigned treatment every day for 12
      months. All patients will begin taking 10 mg once daily, the recommended starting dose. After
      4 weeks, the dose will be increased to 20 mg. In addition to a high standard of diabetes care
      and the medication, patients will have blood tests during 7 visits over an 18 month period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus</measure>
    <time_frame>Baseline vs 12-month</time_frame>
    <description>The change in C-peptide measurements collected over a 4 hour period (0, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) after a Mixed Meal Tolerance Test at baseline vs 12 months post-treatment were calculated. The area under the curve for these combined measurements is calculated and the unit of measure is nanogram x minutes / mL. Efficacy (success) is defined by &lt; 7.5% reduction in AUC for 4-hr MMTT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% Subjects Without Change in 2-hour C-peptide AUC in Response to the MMTT at Baseline vs. 12 Months</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>The C-peptide AUC measurements are collected over a 2 hour period (with 30 minute intervals) after a Mixed Meal Tolerance Test. The area under the curve from these combined measurements (from 0 to 120 or 0 to 240 minutes) is calculated and the unit of measure is nanogram*minutes/ml. The change in C-peptide AUC in response to a 2 hour MMTT at baseline vs 12 months were calculated, and efficacy (success) is defined as &lt; 7.5% reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Insulin Dose Per kg Body Weight for 7 Days</measure>
    <time_frame>Visit 1, 2, 3, 4, 5, 6, 7</time_frame>
    <description>Mean daily insulin dose per kg body weight for the 1 week preceding each scheduled study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of HbA1c at Months 3, 6, 9, 12 and 18</measure>
    <time_frame>3, 6, 9, 12, and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose Control (Number of Participants With Hypoglycemia)</measure>
    <time_frame>Baseline, Month 12, Month 18</time_frame>
    <description>Blood glucose control as determined from home glucose meter downloads for the 1 week preceding the visit. The number of subjects with hypoglycemic episodes requiring treatment (BG &lt; 70 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Hypoglycemia Requiring Any Treatment</measure>
    <time_frame>Baseline, Month 12, Month 18</time_frame>
    <description>number of episodes of hypoglycemia requiring any treatment, defined by the need for treatment with glucagon or third party intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Compliance Rate Overall</measure>
    <time_frame>12 months treatment</time_frame>
    <description>Compliance is defined as &gt;=80% expected dosage consumed during the visit period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function</measure>
    <time_frame>Baseline, Week 1, Month 3, Month 6, Month 9, Month 12,</time_frame>
    <description>Relationship between atorvastatin's effect on HDL and LDL cholesterol and the preservation of islet cell function.
Islet cell preservation defined as: &lt;7.5% Reduction in C-Pep</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two out of every three patients will receive atorvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One out of three subjects will receive a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One out of three subjects will receive a placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals 10-19 years of age (Tanner Stage II or greater),

          -  The presence of one or more serum antibodies to islet cell proteins (anti- glutamic
             acid decarboxylase [GAD], islet antigen 2 or insulin autoantibodies) as assessed in
             standard practice,

          -  Diagnosis of T1DM within the 8 weeks prior to study entry

          -  Peak stimulated C-peptide level &gt;0.2pmol/mL following mixed meal tolerance test (MMTT)
             performed at least 3 weeks after diagnosis,

          -  Females of reproductive potential must not plan on conceiving a child during the
             treatment program, and agree to use a medically accepted form of contraception

        Exclusion Criteria:

          -  Subjects currently receiving cyclosporine, fibric acid derivatives, niacin (nicotinic
             acid), erythromycin, clarythromycin, nefazodone, itraconazole, ketoconazole or
             protease inhibitors,

          -  Pregnancy or breast-feeding,

          -  Clinical AIDS, AIDS related syndrome (ARS) or known positive HIV serology,

          -  Subjects treated with immunosuppressive therapy in the past 12 months,

          -  Subjects receiving glucocorticoid therapy or therapy other than insulin that is likely
             to affect glucose homeostasis (such as sulfonylureas, thiazolidinediones, metformin or
             amylin),

          -  Subjects with other autoimmune diseases, except autoimmune thyroid disease,

          -  Subjects with any illness that might complicate diabetes management or preclude
             treatment with atorvastatin,

          -  Transplant recipients,

          -  Evidence of liver dysfunction or myopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Willi, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Center for Children &amp; Clinical Translational Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>December 20, 2012</results_first_submitted>
  <results_first_submitted_qc>February 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2013</results_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I Diabetes (T1DM)</keyword>
  <keyword>Atorvastatin (Lipitor)</keyword>
  <keyword>Insulin</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Beta Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share these data, except in aggregate.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from medical clinics at CHOP from July 2007- January 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>Two out of every 3 patients will receive atorvastatin in tablet form. The subject will start on 10mg of atorvastatin daily for four weeks, and then titrate up to 20mg daily. There will be 12 months of treatment followed by 6 months of a washout period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo treated. Patients will receive tablets daily.There will be 12 months of treatment followed by 6 months of a washout period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>Two out of every 3 patients will receive atorvastatin.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.38" spread="1.96"/>
                    <measurement group_id="B2" value="13.30" spread="2.03"/>
                    <measurement group_id="B3" value="13.33" spread="2.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus</title>
        <description>The change in C-peptide measurements collected over a 4 hour period (0, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) after a Mixed Meal Tolerance Test at baseline vs 12 months post-treatment were calculated. The area under the curve for these combined measurements is calculated and the unit of measure is nanogram x minutes / mL. Efficacy (success) is defined by &lt; 7.5% reduction in AUC for 4-hr MMTT.</description>
        <time_frame>Baseline vs 12-month</time_frame>
        <population>Participants who completed their 12-month treatment were included in the analysis, in which the change in C-peptide AUC at baseline and 12-months were calculated. Efficacy (success) is defined by &lt; 7.5% reduction in AUC for 4-hr MMTT.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Two out of every 3 patients will receive atorvastatin.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus</title>
          <description>The change in C-peptide measurements collected over a 4 hour period (0, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) after a Mixed Meal Tolerance Test at baseline vs 12 months post-treatment were calculated. The area under the curve for these combined measurements is calculated and the unit of measure is nanogram x minutes / mL. Efficacy (success) is defined by &lt; 7.5% reduction in AUC for 4-hr MMTT.</description>
          <population>Participants who completed their 12-month treatment were included in the analysis, in which the change in C-peptide AUC at baseline and 12-months were calculated. Efficacy (success) is defined by &lt; 7.5% reduction in AUC for 4-hr MMTT.</population>
          <units>nanogram*minutes/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345" spread="679"/>
                    <measurement group_id="O2" value="178" spread="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Subjects Without Change in 2-hour C-peptide AUC in Response to the MMTT at Baseline vs. 12 Months</title>
        <description>The C-peptide AUC measurements are collected over a 2 hour period (with 30 minute intervals) after a Mixed Meal Tolerance Test. The area under the curve from these combined measurements (from 0 to 120 or 0 to 240 minutes) is calculated and the unit of measure is nanogram*minutes/ml. The change in C-peptide AUC in response to a 2 hour MMTT at baseline vs 12 months were calculated, and efficacy (success) is defined as &lt; 7.5% reduction.</description>
        <time_frame>Baseline vs 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Two out of every 3 patients will receive atorvastatin.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment</description>
          </group>
        </group_list>
        <measure>
          <title>% Subjects Without Change in 2-hour C-peptide AUC in Response to the MMTT at Baseline vs. 12 Months</title>
          <description>The C-peptide AUC measurements are collected over a 2 hour period (with 30 minute intervals) after a Mixed Meal Tolerance Test. The area under the curve from these combined measurements (from 0 to 120 or 0 to 240 minutes) is calculated and the unit of measure is nanogram*minutes/ml. The change in C-peptide AUC in response to a 2 hour MMTT at baseline vs 12 months were calculated, and efficacy (success) is defined as &lt; 7.5% reduction.</description>
          <units>% of participants with efficacy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Insulin Dose Per kg Body Weight for 7 Days</title>
        <description>Mean daily insulin dose per kg body weight for the 1 week preceding each scheduled study visit.</description>
        <time_frame>Visit 1, 2, 3, 4, 5, 6, 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Two out of every three patients will receive atorvastatin.
Atorvastatin: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treated. Patients will receive tablets daily.There will be 12 months of treatment followed by 6 months of a washout period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Insulin Dose Per kg Body Weight for 7 Days</title>
          <description>Mean daily insulin dose per kg body weight for the 1 week preceding each scheduled study visit.</description>
          <units>units/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.26"/>
                    <measurement group_id="O2" value="0.62" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.25"/>
                    <measurement group_id="O2" value="0.52" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.21"/>
                    <measurement group_id="O2" value="0.50" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.21"/>
                    <measurement group_id="O2" value="0.47" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.22"/>
                    <measurement group_id="O2" value="0.59" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.24"/>
                    <measurement group_id="O2" value="0.64" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.35"/>
                    <measurement group_id="O2" value="0.71" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of HbA1c at Months 3, 6, 9, 12 and 18</title>
        <time_frame>3, 6, 9, 12, and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Two out of every three patients will receive atorvastatin.
Atorvastatin: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One out of three subjects will receive a placebo.
Placebo: One out of three subjects will receive a placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of HbA1c at Months 3, 6, 9, 12 and 18</title>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.68" spread="0.95"/>
                    <measurement group_id="O2" value="6.39" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.13" spread="0.90"/>
                    <measurement group_id="O2" value="6.62" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.47" spread="1.44"/>
                    <measurement group_id="O2" value="6.86" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.38" spread="1.19"/>
                    <measurement group_id="O2" value="7.26" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" spread="1.82"/>
                    <measurement group_id="O2" value="7.94" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Glucose Control (Number of Participants With Hypoglycemia)</title>
        <description>Blood glucose control as determined from home glucose meter downloads for the 1 week preceding the visit. The number of subjects with hypoglycemic episodes requiring treatment (BG &lt; 70 mg/dl)</description>
        <time_frame>Baseline, Month 12, Month 18</time_frame>
        <population>All participants contributing data</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Participants in Atorvastatin arm who had hypoglycemic episodes requiring treatment
Two out of every three patients will receive atorvastatin.
Atorvastatin: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in placebo arm who had hypoglycemic episodes requiring treatment
Placebo treated. Patients will receive tablets daily.There will be 12 months of treatment followed by 6 months of a washout period.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Control (Number of Participants With Hypoglycemia)</title>
          <description>Blood glucose control as determined from home glucose meter downloads for the 1 week preceding the visit. The number of subjects with hypoglycemic episodes requiring treatment (BG &lt; 70 mg/dl)</description>
          <population>All participants contributing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Hypoglycemia Requiring Any Treatment</title>
        <description>number of episodes of hypoglycemia requiring any treatment, defined by the need for treatment with glucagon or third party intervention.</description>
        <time_frame>Baseline, Month 12, Month 18</time_frame>
        <population>All subjects contributing data</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Participants in Atorvastatin arm who had hypoglycemic episodes requiring treatment
Two out of every three patients will receive atorvastatin.
Atorvastatin: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in placebo arm who had hypoglycemic episodes requiring treatment
Placebo treated. Patients will receive tablets daily.There will be 12 months of treatment followed by 6 months of a washout period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Hypoglycemia Requiring Any Treatment</title>
          <description>number of episodes of hypoglycemia requiring any treatment, defined by the need for treatment with glucagon or third party intervention.</description>
          <population>All subjects contributing data</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="3.95"/>
                    <measurement group_id="O2" value="2.86" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="3.01"/>
                    <measurement group_id="O2" value="2.44" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="3.65"/>
                    <measurement group_id="O2" value="2.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Compliance Rate Overall</title>
        <description>Compliance is defined as &gt;=80% expected dosage consumed during the visit period.</description>
        <time_frame>12 months treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Two out of every three patients will receive atorvastatin.
Atorvastatin: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treated. Patients will receive tablets daily.There will be 12 months of treatment followed by 6 months of a washout period.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Compliance Rate Overall</title>
          <description>Compliance is defined as &gt;=80% expected dosage consumed during the visit period.</description>
          <units>% of compliant participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1"/>
                    <measurement group_id="O2" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function</title>
        <description>Relationship between atorvastatin's effect on HDL and LDL cholesterol and the preservation of islet cell function.
Islet cell preservation defined as: &lt;7.5% Reduction in C-Pep</description>
        <time_frame>Baseline, Week 1, Month 3, Month 6, Month 9, Month 12,</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin NO Islet Cell Preservation</title>
            <description>Two out of every three patients will receive atorvastatin.
Atorvastatin: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo NO Islet Cell Preservation</title>
            <description>Placebo treated. Patients will receive tablets daily.There will be 12 months of treatment followed by 6 months of a washout period.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin YES Islet Cell Preservation</title>
            <description>Two out of every three patients will receive atorvastatin.
Atorvastatin: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months</description>
          </group>
          <group group_id="O4">
            <title>Placebo YES Islet Cell Preservation</title>
            <description>Placebo treated. Patients will receive tablets daily.There will be 12 months of treatment followed by 6 months of a washout period.</description>
          </group>
        </group_list>
        <measure>
          <title>HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function</title>
          <description>Relationship between atorvastatin's effect on HDL and LDL cholesterol and the preservation of islet cell function.
Islet cell preservation defined as: &lt;7.5% Reduction in C-Pep</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline- HDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.58" spread="16.39"/>
                    <measurement group_id="O2" value="44.75" spread="18"/>
                    <measurement group_id="O3" value="47.33" spread="2.31"/>
                    <measurement group_id="O4" value="53.2" spread="16.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - LDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.04" spread="22.37"/>
                    <measurement group_id="O2" value="96.13" spread="22.99"/>
                    <measurement group_id="O3" value="83.67" spread="25.97"/>
                    <measurement group_id="O4" value="99" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1- HDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.43" spread="14.33"/>
                    <measurement group_id="O2" value="48.25" spread="14.26"/>
                    <measurement group_id="O3" value="52.33" spread="5.69"/>
                    <measurement group_id="O4" value="47.2" spread="13.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 - LDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.91" spread="16.4"/>
                    <measurement group_id="O2" value="97.63" spread="17.9"/>
                    <measurement group_id="O3" value="57.67" spread="12.06"/>
                    <measurement group_id="O4" value="86.4" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3- HDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="14.49"/>
                    <measurement group_id="O2" value="48.25" spread="18.69"/>
                    <measurement group_id="O3" value="43.33" spread="4.04"/>
                    <measurement group_id="O4" value="49.25" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 - LDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="20.88"/>
                    <measurement group_id="O2" value="106.25" spread="18.44"/>
                    <measurement group_id="O3" value="48" spread="12.17"/>
                    <measurement group_id="O4" value="91.5" spread="20.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6- HDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="16.07"/>
                    <measurement group_id="O2" value="50.5" spread="20.7"/>
                    <measurement group_id="O3" value="51.67" spread="5.51"/>
                    <measurement group_id="O4" value="54.75" spread="19.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - LDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="24.52"/>
                    <measurement group_id="O2" value="102.5" spread="16.21"/>
                    <measurement group_id="O3" value="54" spread="7"/>
                    <measurement group_id="O4" value="96.75" spread="20.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9- HDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="14.86"/>
                    <measurement group_id="O2" value="45.88" spread="12.57"/>
                    <measurement group_id="O3" value="55.33" spread="11.15"/>
                    <measurement group_id="O4" value="50" spread="21.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 - LDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.24" spread="24.7"/>
                    <measurement group_id="O2" value="97" spread="4.17"/>
                    <measurement group_id="O3" value="65.33" spread="28.01"/>
                    <measurement group_id="O4" value="90.75" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - HDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.95" spread="14.49"/>
                    <measurement group_id="O2" value="45.75" spread="16.34"/>
                    <measurement group_id="O3" value="57.33" spread="14.15"/>
                    <measurement group_id="O4" value="47" spread="8.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 - LDL Cholesterol (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.52" spread="20.04"/>
                    <measurement group_id="O2" value="102.75" spread="20.9"/>
                    <measurement group_id="O3" value="66" spread="23.64"/>
                    <measurement group_id="O4" value="96.4" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events were reported over the one year treatment phase of the study.</time_frame>
      <desc>Adverse events were reported or observed at interim visits, and were systematically collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>Two out of every 3 patients will receive atorvastatin.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Reported or observed at interim visit.</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Reported or observed at interim visit.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Reported or observed at interim visit.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Reported or observed at interim visit.</description>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Patient report of headache at interim assessment.</description>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <description>Reported or observed at interim visit.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory Infection</sub_title>
                <description>Respiratory Infection reported or observed at interim visit.</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <description>Reported or observed at interim visit.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Willi, MD</name_or_title>
      <organization>Children's Hospital of Philadelphia</organization>
      <phone>215-590-3174</phone>
      <email>willi@chop.email.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

